CN106459979B - 用于结合补体组分3蛋白的核酸化合物 - Google Patents

用于结合补体组分3蛋白的核酸化合物 Download PDF

Info

Publication number
CN106459979B
CN106459979B CN201580028344.6A CN201580028344A CN106459979B CN 106459979 B CN106459979 B CN 106459979B CN 201580028344 A CN201580028344 A CN 201580028344A CN 106459979 B CN106459979 B CN 106459979B
Authority
CN
China
Prior art keywords
aptamer
protein
seq
deoxyuridine
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580028344.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459979A (zh
Inventor
丹尼尔·W·德罗莱
张弛
丹尼尔·J·奥康奈尔
沙希·古普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Private Placement Protein Body Operation Co ltd
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Priority to CN201910922493.7A priority Critical patent/CN110643610A/zh
Publication of CN106459979A publication Critical patent/CN106459979A/zh
Application granted granted Critical
Publication of CN106459979B publication Critical patent/CN106459979B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
CN201580028344.6A 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物 Expired - Fee Related CN106459979B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910922493.7A CN110643610A (zh) 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462005300P 2014-05-30 2014-05-30
US62/005,300 2014-05-30
PCT/US2015/033355 WO2015184372A1 (en) 2014-05-30 2015-05-29 Nucleic acid compounds for binding to complement component 3 protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910922493.7A Division CN110643610A (zh) 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物

Publications (2)

Publication Number Publication Date
CN106459979A CN106459979A (zh) 2017-02-22
CN106459979B true CN106459979B (zh) 2020-07-21

Family

ID=53398218

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580028344.6A Expired - Fee Related CN106459979B (zh) 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物
CN201910922493.7A Pending CN110643610A (zh) 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910922493.7A Pending CN110643610A (zh) 2014-05-30 2015-05-29 用于结合补体组分3蛋白的核酸化合物

Country Status (8)

Country Link
US (2) US11466275B2 (cg-RX-API-DMAC7.html)
EP (1) EP3149173B1 (cg-RX-API-DMAC7.html)
JP (1) JP6824041B2 (cg-RX-API-DMAC7.html)
CN (2) CN106459979B (cg-RX-API-DMAC7.html)
CA (1) CA2949246C (cg-RX-API-DMAC7.html)
ES (1) ES2664179T3 (cg-RX-API-DMAC7.html)
NO (1) NO2718257T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015184372A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312346B (zh) * 2016-07-01 2024-07-30 私募蛋白质体操作有限公司 包含修饰核苷的寡核苷酸
US12202848B2 (en) * 2019-10-18 2025-01-21 Fujifilm Wako Pure Chemical Corporation Phosphoramidite activator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374965A (zh) * 2006-01-17 2009-02-25 私募蛋白质体公司 测试样品的多元化分析

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
WO1997042317A1 (en) 1996-05-07 1997-11-13 T Cell Sciences, Inc. APTAMERS FOR COMPLEMENT PROTEIN C3b
US20020082227A1 (en) * 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US20030219801A1 (en) * 2002-03-06 2003-11-27 Affymetrix, Inc. Aptamer base technique for ligand identification
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) * 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8927509B2 (en) * 2008-05-20 2015-01-06 The Research Foundation Of State University Of New York Aptamer modulators of complement protein C3 and biologically active proteolytic products thereof
EP2558478B1 (en) 2010-04-12 2018-03-07 Somalogic, Inc. 5-position modified pyrimidines and their use
EP2683729B1 (en) * 2011-03-10 2017-05-03 Somalogic, Inc. Aptamers for clostridium difficile diagnostics
WO2013152024A1 (en) 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor c3 antibodies and uses thereof
KR20240144493A (ko) * 2016-08-24 2024-10-02 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
JP7661299B2 (ja) * 2019-07-11 2025-04-14 メモリアル スローン ケタリング キャンサー センター Ｄｌｌ３をターゲッティングする抗体とその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101374965A (zh) * 2006-01-17 2009-02-25 私募蛋白质体公司 测试样品的多元化分析

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Commandeering a biological pathway using aptamer-derived molecular adaptors;Prabhat等;《Nucleic Acids Research》;20100106;第38卷(第7期);第2页左栏2-3段、最后两段及第3页左栏第3段 *
核酸适体的筛选制备及分析应用;刘腾飞等;《生物技术通报》;20131231;第39-48页 *

Also Published As

Publication number Publication date
CN106459979A (zh) 2017-02-22
WO2015184372A1 (en) 2015-12-03
CA2949246A1 (en) 2015-12-03
NO2718257T3 (cg-RX-API-DMAC7.html) 2018-04-14
US20170166895A1 (en) 2017-06-15
CN110643610A (zh) 2020-01-03
US20230093170A1 (en) 2023-03-23
JP2017517261A (ja) 2017-06-29
EP3149173A1 (en) 2017-04-05
US11466275B2 (en) 2022-10-11
EP3149173B1 (en) 2018-02-07
CA2949246C (en) 2023-06-27
JP6824041B2 (ja) 2021-02-03
ES2664179T3 (es) 2018-04-18

Similar Documents

Publication Publication Date Title
US9410156B2 (en) Aptamers to PDGF and VEGF and their use in treating PDGF and VEGF mediated conditions
AU2011223527B2 (en) Aptamers to 4-1BB and their use in treating diseases and disorders
KR102242874B1 (ko) Ｉｌ―６에 결합하는 압타머 및 ｉｌ―６ 매개된 질환을 치료하거나 진단하는 데에서 이의 용도
US10544419B2 (en) PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
US20230093170A1 (en) Nucleic Acid Compounds for Binding to Complement Component 3 Protein
US20220333113A1 (en) Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein
HK40018876A (en) Nucleic acid compounds for binding to complement component 3 protein
HK40033269A (en) Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
HK1204014B (en) Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Colorado, USA

Patentee after: Private placement protein body Operation Co.,Ltd.

Address before: Colorado, USA

Patentee before: SOMALOGIC, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200721